Literature DB >> 9271418

Distinct tyrosine autophosphorylation sites negatively and positively modulate neu-mediated transformation.

D L Dankort1, Z Wang, V Blackmore, M F Moran, W J Muller.   

Abstract

A number of cytoplasmic signaling molecules are thought to mediate mitogenic signaling from the activated Neu receptor tyrosine kinase through binding specific phosphotyrosine residues located within the intracellular portion of Neu/c-ErbB-2. An activated neu oncogene containing tyrosine-to-phenylalanine substitutions at each of the known autophosphorylation sites was generated and assessed for its specific transforming potential in Rat1 and NIH 3T3 fibroblasts. Mutation of these sites resulted in a dramatic impairment of the transforming potential of neu. To assess the role of these tyrosine phosphorylation sites in cellular transformation, the transforming potential of a series of mutants in which individual tyrosine residues were restored to this transformation-debilitated neu mutant was evaluated. Reversion of any one of four mutated sites to tyrosine residues restored wild-type transforming activity. While each of these transforming mutants displayed Ras-dependent signaling, the transforming activity of two of these mutants was correlated with their ability to bind either the GRB2 or SHC adapter molecules that couple receptor tyrosine kinases to the Ras signaling pathway. By contrast, restoration of a tyrosine residue located at position 1028 completely suppressed the basal transforming activity of this mutated neu molecule or other transforming neu molecules which possessed single tyrosine residues. These data argue that the transforming potential of activated neu is mediated both by positive and negative regulatory tyrosine phosphorylation sites.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9271418      PMCID: PMC232391          DOI: 10.1128/MCB.17.9.5410

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  74 in total

1.  Cellular ras activity is required for passage through multiple points of the G0/G1 phase in BALB/c 3T3 cells.

Authors:  S Dobrowolski; M Harter; D W Stacey
Journal:  Mol Cell Biol       Date:  1994-08       Impact factor: 4.272

2.  CRK protein binds to two guanine nucleotide-releasing proteins for the Ras family and modulates nerve growth factor-induced activation of Ras in PC12 cells.

Authors:  M Matsuda; Y Hashimoto; K Muroya; H Hasegawa; T Kurata; S Tanaka; S Nakamura; S Hattori
Journal:  Mol Cell Biol       Date:  1994-08       Impact factor: 4.272

3.  Formation of Shc-Grb2 complexes is necessary to induce neoplastic transformation by overexpression of Shc proteins.

Authors:  A E Salcini; J McGlade; G Pelicci; I Nicoletti; T Pawson; P G Pelicci
Journal:  Oncogene       Date:  1994-10       Impact factor: 9.867

4.  Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors.

Authors:  P M Siegel; D L Dankort; W R Hardy; W J Muller
Journal:  Mol Cell Biol       Date:  1994-11       Impact factor: 4.272

5.  Tyr-716 in the platelet-derived growth factor beta-receptor kinase insert is involved in GRB2 binding and Ras activation.

Authors:  A K Arvidsson; E Rupp; E Nånberg; J Downward; L Rönnstrand; S Wennström; J Schlessinger; C H Heldin; L Claesson-Welsh
Journal:  Mol Cell Biol       Date:  1994-10       Impact factor: 4.272

6.  Specific motifs recognized by the SH2 domains of Csk, 3BP2, fps/fes, GRB-2, HCP, SHC, Syk, and Vav.

Authors:  Z Songyang; S E Shoelson; J McGlade; P Olivier; T Pawson; X R Bustelo; M Barbacid; H Sabe; H Hanafusa; T Yi
Journal:  Mol Cell Biol       Date:  1994-04       Impact factor: 4.272

7.  Hierarchy of binding sites for Grb2 and Shc on the epidermal growth factor receptor.

Authors:  A G Batzer; D Rotin; J M Ureña; E Y Skolnik; J Schlessinger
Journal:  Mol Cell Biol       Date:  1994-08       Impact factor: 4.272

Review 8.  Prognostic factors in early breast carcinoma.

Authors:  E G Mansour; P M Ravdin; L Dressler
Journal:  Cancer       Date:  1994-07-01       Impact factor: 6.860

9.  The SH2 domain protein GRB-7 is co-amplified, overexpressed and in a tight complex with HER2 in breast cancer.

Authors:  D Stein; J Wu; S A Fuqua; C Roonprapunt; V Yajnik; P D'Eustachio; J J Moskow; A M Buchberg; C K Osborne; B Margolis
Journal:  EMBO J       Date:  1994-03-15       Impact factor: 11.598

10.  A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway.

Authors:  R Ben-Levy; H F Paterson; C J Marshall; Y Yarden
Journal:  EMBO J       Date:  1994-07-15       Impact factor: 11.598

View more
  54 in total

1.  Regulation of neuregulin-mediated acetylcholine receptor synthesis by protein tyrosine phosphatase SHP2.

Authors:  M Tanowitz; J Si; D H Yu; G S Feng; L Mei
Journal:  J Neurosci       Date:  1999-11-01       Impact factor: 6.167

2.  Rotational coupling of the transmembrane and kinase domains of the Neu receptor tyrosine kinase.

Authors:  C A Bell; J A Tynan; K C Hart; A N Meyer; S C Robertson; D J Donoghue
Journal:  Mol Biol Cell       Date:  2000-10       Impact factor: 4.138

Review 3.  The ErbB signaling network: receptor heterodimerization in development and cancer.

Authors:  M A Olayioye; R M Neve; H A Lane; N E Hynes
Journal:  EMBO J       Date:  2000-07-03       Impact factor: 11.598

4.  Receptor tyrosine kinase signaling favors a protumorigenic state in breast cancer cells by inhibiting the adaptive immune response.

Authors:  Josie Ursini-Siegel; Sean Cory; Dongmei Zuo; William R Hardy; Elton Rexhepaj; Sonya Lam; Babette Schade; Karin Jirstrom; Eva Bjur; Ciriaco A Piccirillo; David Denardo; Lisa M Coussens; Donal J Brennan; William M Gallagher; Morag Park; Tony Pawson; Michael Hallett; William J Muller
Journal:  Cancer Res       Date:  2010-10-05       Impact factor: 12.701

Review 5.  The ErbB2 signaling network as a target for breast cancer therapy.

Authors:  Ali Badache; Anthony Gonçalves
Journal:  J Mammary Gland Biol Neoplasia       Date:  2006-01       Impact factor: 2.673

6.  Screening for PTB domain binding partners and ligand specificity using proteome-derived NPXY peptide arrays.

Authors:  Matthew J Smith; W Rod Hardy; James M Murphy; Nina Jones; Tony Pawson
Journal:  Mol Cell Biol       Date:  2006-09-18       Impact factor: 4.272

7.  Muc4-ErbB2 complex formation and signaling in polarized CACO-2 epithelial cells indicate that Muc4 acts as an unorthodox ligand for ErbB2.

Authors:  Victoria P Ramsauer; Vanessa Pino; Amjad Farooq; Coralie A Carothers Carraway; Pedro J I Salas; Kermit L Carraway
Journal:  Mol Biol Cell       Date:  2006-04-19       Impact factor: 4.138

8.  ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner.

Authors:  M A Olayioye; D Graus-Porta; R R Beerli; J Rohrer; B Gay; N E Hynes
Journal:  Mol Cell Biol       Date:  1998-09       Impact factor: 4.272

9.  Activation of Neu (ErbB-2) mediated by disulfide bond-induced dimerization reveals a receptor tyrosine kinase dimer interface.

Authors:  C L Burke; D F Stern
Journal:  Mol Cell Biol       Date:  1998-09       Impact factor: 4.272

10.  Phosphatase and tensin homologue deleted on chromosome 10 deficiency accelerates tumor induction in a mouse model of ErbB-2 mammary tumorigenesis.

Authors:  Nathalie Dourdin; Babette Schade; Robert Lesurf; Michael Hallett; Robert J Munn; Robert D Cardiff; William J Muller
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.